Research & Development: Page 61

  • Image attribution tooltip
    PharmaVoice Team/PharmaVoice
    Image attribution tooltip

    Reader Feedback

    Who Inspires You? PharmaVOICE Wants to Know! Each year the PharmaVOICE 100 is determined by the collective participation of you, our readers. This is your opportunity to recognize the people who inspire and motivate you and others; who are having the greatest influence on corporate leadership, re...

    By PharmaVoice Team • March 3, 2011
  • Image attribution tooltip
    PharmaVoice Team/PharmaVoice
    Image attribution tooltip

    Letter from the Editor

    Cheers! Time flies when one is having fun. And the last 10 years have been extremely fun and extremely rewarding. It’s been great getting to know so many of you throughout the life-sciences industry. Back in 2001, the term life-sciences was not common, in fact many questioned us as to what it mea...

    By PharmaVoice Team • March 3, 2011
  • cancer healthcare Explore the Trendline➔
    Image attribution tooltip
    Stock via Getty Images
    Image attribution tooltip
    Trendline

    Oncology

    As investments in cancer R&D stay high, waves of innovative new treatments are on the horizon.

    By PharmaVoice staff
  • Image attribution tooltip
    PharmaVoice Team/PharmaVoice
    Image attribution tooltip

    SHOWCASE FEATURE: Unclogging the Patient Recruitment Bottleneck

    The increased complexity of clinical trial design and the trend toward more targeted patient populations necessitates rethinking the traditional methods of patient recruitment to ­overcome failure and timeline extensions. Patient recruitment remains to be one of the biggest, and most costly, bott...

    By Taren Grom • Jan. 26, 2011
  • Image attribution tooltip
    PharmaVoice Team/PharmaVoice
    Image attribution tooltip

    M&A: A Short-Term Solution Whose Time May Be Over

    2009 was punctuated by the latest and greatest round of major pharmaceutical company mergers, with the big three — Merck and Schering-Plough, Pfizer and Wyeth, and Roche and Genentech — shining a spotlight on M&A practices in the industry. In reality, M&A has always been a growth strategy...

    By Robin Robinson • Jan. 26, 2011
  • Image attribution tooltip
    PharmaVoice Team/PharmaVoice
    Image attribution tooltip

    Developing A True Strategic Partnership

    The biopharmaceutical industry is facing intense pressure within research and development to bring new drugs to the market at a time when drug development has become complex and expensive. Blockbuster patent expirations, more complex protocols, increasing R&D costs, patient recruitment issues...

    By PharmaVoice Team • Jan. 26, 2011
  • Image attribution tooltip
    PharmaVoice Team/PharmaVoice
    Image attribution tooltip

    Last Word

    PV: What should the goals of a corporate social media program be? Adler: There are many opportunities for companies to engage in social media; generally these fall into three categories. Certainly, chief among the reasons to embark upon a proactive social media program is to enhance awareness amo...

    By PharmaVoice Team • Jan. 26, 2011
  • Image attribution tooltip
    PharmaVoice Team/PharmaVoice
    Image attribution tooltip

    Talent Pool

    Pharmaceutical POOL Robert DAVIS Dr. Ludwig HANTSON Baxter International Forms Medical Products Business Baxter International has appointed Robert Davis corporate VP and president of its newly created medical products business, which combines the company’s renal and medication delivery businesses...

    By PharmaVoice Team • Jan. 26, 2011
  • Image attribution tooltip
    PharmaVoice Team/PharmaVoice
    Image attribution tooltip

    Tools of the Trade

    New Platforms Streamline Scientific Data Sharing Trends: Service providers are harnessing the power of user-generated applications and SaaS to help take scientific search and discovery to the next level.   Elsevier’S SCIVERSE APPLICATIONS beta, a new module within the SciVerse content database pl...

    By PharmaVoice Team • Jan. 26, 2011
  • Image attribution tooltip
    PharmaVoice Team/PharmaVoice
    Image attribution tooltip

    What's New

    Trend: As the healthcare industry continues to consolidate and rationalize, pharma and biotech companies increasingly need a communications partner that understands how to reach both ­professional and consumer audiences across traditional and digital channels. New Focus on Digital Healthcare Stra...

    By PharmaVoice Team • Jan. 26, 2011
  • Image attribution tooltip
    PharmaVoice Team/PharmaVoice
    Image attribution tooltip

    PharmaTrax

    Trend: With its traditional business model breaking down amid scant financing and lengthy R&D processes, the biotech sector needs to reinvent itself by adopting a more collaborative ­approach to capitalize on emerging healthcare opportunities. According to the PricewaterhouseCoopers (PwC) rep...

    By PharmaVoice Team • Jan. 26, 2011
  • Image attribution tooltip
    PharmaVoice Team/PharmaVoice
    Image attribution tooltip

    UpFront

    Awards… Cephalon wins PRSA Awards CRF Health Wins at Clio Natrel Wins Rx Club Award INDUSTRY at Large Smarty Apps… E-Promotion on the E-Rise Supporting Science Education Lucky 14 Pharma Saves Green by Going Green Disruptive Technology, Disruptive times Top Innovators Podcasts Best Practices for Y...

    By PharmaVoice Team • Jan. 26, 2011
  • Image attribution tooltip
    PharmaVoice Team/PharmaVoice
    Image attribution tooltip

    Letter from the Editor

    Pharma 3.0: Are you ready? The era of Pharma 3.0 is upon us. According to Ernst & Young (EY), several industry trends, including healthcare reform, health IT, comparative effectiveness, and the rising confidence in consumer power, are driving nontraditional companies into the life-sciences se...

    By Taren Grom • Jan. 26, 2011
  • Image attribution tooltip
    PharmaVoice Team/PharmaVoice
    Image attribution tooltip

    Emerging Market: Ola Brazil

    With every passing year, the pharmaceutical industry becomes more global in its ­ outlook and reach. In recognition of our shrinking world, PharmaVOICE is taking you on a journey across the globe. Our first stop is Latin America’s largest market, Brazil. Brazil is familiar territory to the pharma...

    By Kim Ribbink • Dec. 27, 2010
  • Image attribution tooltip
    PharmaVoice Team/PharmaVoice
    Image attribution tooltip

    Last Word

    Pharma Forecast Simon King, a pharmaceutical company analyst at ­Datamonitor, comments on trends expected to impact “big pharma" in 2011. PV: Despite a challenging year for Roche, you say restructuring will help the company maintain a strong fiscal position. What other factors do you think will h...

    By PharmaVoice Team • Dec. 27, 2010
  • Image attribution tooltip
    PharmaVoice Team/PharmaVoice
    Image attribution tooltip

    Talent Pool

    Pharmaceutical POOL Dr. Milind DESHPANDE Achillion Pharmaceuticals Promotes R&D President Achillion Pharmaceuticals, which is focused on the discovery and development of small-molecule drugs to combat challenging infectious diseases, has promoted Chief Scientific Officer Milind Deshpande, Ph....

    By PharmaVoice Team • Dec. 27, 2010
  • Image attribution tooltip
    PharmaVoice Team/PharmaVoice
    Image attribution tooltip

    Tools of the Trade

    New Electronic and Web-based Applications, Sites, and Technologies Featured Briefs: New Solutions Help Harness Social Monitoring Insights CRM Update In Other Technology News… AstraZeneca BioClinica Chiltern International Cmed Technology Decision Resources PharmaVigilant E-Upgrades and Enhancement...

    By PharmaVoice Team • Dec. 27, 2010
  • Image attribution tooltip
    PharmaVoice Team/PharmaVoice
    Image attribution tooltip

    What's New

    Trends: Changing market forces and the trend toward more flexible business models have inspired the creation of dynamic companies better positioned to explore opportunities ­overlooked by larger life-sciences organizations. NEW AMERICAN THERAPEUTICS, a specialty pharmaceutical company co-founded ...

    By PharmaVoice Team • Dec. 27, 2010
  • Image attribution tooltip
    PharmaVoice Team/PharmaVoice
    Image attribution tooltip

    PharmaTrax

    Sales, Marketing, and R&D Trends from Industry Analysts Featured Briefs: A Consistent Life-Cycle Management Strategy Can Counter Market Threats Innovation Remains Key to Drug Approval ­Strategy Sidebars: First-Cycle Approval Rates for Original NDAs (FY2003-FY2009) LCM Strategy Targeting Can M...

    By PharmaVoice Team • Dec. 27, 2010
  • Image attribution tooltip
    PharmaVoice Team/PharmaVoice
    Image attribution tooltip

    Reader Feedback

    Transforming R&D It was noted in your ­November/December Year in Preview ­article “Transforming R&D" that life-sciences companies are experiencing “the perfect storm." I believe it’s more like a tsunami. Tsunamis are typically generated by a massive disturbance such as an earthquake, volc...

    By PharmaVoice Team • Dec. 27, 2010
  • Image attribution tooltip
    PharmaVoice Team/PharmaVoice
    Image attribution tooltip

    Letter from the Editor

    Happy New Decade! Happy New Year to all from ­everybody at PharmaVOICE. We wish you a year of health, peace, and prosperity. As we ring in 2011, it’s not just a new year and a new decade, but PharmaVOICE is celebrating its 10th Anniversary! Time certainly does fly when having fun (and working har...

    By Taren Grom • Dec. 27, 2010
  • Image attribution tooltip
    PharmaVoice Team/PharmaVoice
    Image attribution tooltip

    Global R&D

    The globalization of clinical studies has been driven by several factors, including the need to access larger patient populations for the larger Phase III, Phase IV, or safety trials, and the need to reduce the expense of conducting those trials by taking advantage of high-quality, lower-cost cli...

    By Denise Myshko • Nov. 12, 2010
  • Image attribution tooltip
    PharmaVoice Team/PharmaVoice
    Image attribution tooltip

    The Year Ahead - The Next Wave of Challenges

    In this special issue of PharmaVOICE, industry leaders take a look at the challenges they expect to face in the coming year and beyond, as well as some of the strategies to deal with these issues. One trend identified by many is the influence of different markets around the world as countries con...

    By Denise Myshko • Nov. 10, 2010
  • Image attribution tooltip
    PharmaVoice Team/PharmaVoice
    Image attribution tooltip

    A Globally Focused Industry

    There will be an overall shift in the pharmaceutical industry from a very Western-centric model to a global one. Disease areas that were once considered niche are now given priority and the more prevalent disease therapeutic areas in the mature markets have taken a backseat. Vaccines, biologics, ...

    By Denise Myshko • Nov. 10, 2010
  • Image attribution tooltip
    PharmaVoice Team/PharmaVoice
    Image attribution tooltip

    Continued Outsourcing Expected

    While global spending on new drug development has been growing at an annual rate of 9.1% during this past decade, spending on contract clinical services has been growing almost 50% faster, at an annual rate of 13.4%, according to the Tufts Center for the Study of Drug Development. Even as the num...

    By Denise Myshko • Nov. 10, 2010
  • Image attribution tooltip
    PharmaVoice Team/PharmaVoice
    Image attribution tooltip

    A Renewed Focus on the Pipeline

    Despite steady and significant increases in R&D spending, the number of new molecular entities (NMEs) and biologic license applications (BLAs) approved have been declining over recent years. Current biopharma R&D operating models lack the flexibility required to effectively apply research...

    By Denise Myshko • Nov. 10, 2010